The Effectiveness of Ondonestrone and Granisetron in the Treatment of Obsessive-Compulsive Disorder

Phase 3

• Conditions: obsessive-compulsive disorder.; Obsessive-compulsive disorder

• Registration Number: IRCT20130726014170N2
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 May 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Diagnosis of OCD established by clinical interview (using The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) Axis I Disorders)
Resistant or inadequacy of Serotonin reuptake inhibitor (SRIs) treatment response

Exclusion Criteria

Diagnosis of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, substance dependence or abuse, and other comorbid DSM-IV Axis I disorders
History of seizure, suicidal ideation? and significant head trauma
Recent receiving antipsychotics in the treatment of obsessive-compulsive disorder
Intelligence quotient less than 70
history of treatment resistance
pregnancy and/or lactation
Having significant cardiovascular, hepatic, renal or pulmonary diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes from baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) total, Obsession and Compulsion subscale score. Timepoint: Every two weeks for 18 weeks. Method of measurement: Yale-Brown Obsessive Compulsive Scale (YBOCS).

Secondary Outcome Measures

Name	Time	Method
Partial treatment response. Timepoint: Every two weeks for 18 weeks. Method of measurement: Yale-Brown Obsessive Compulsive Scale (YBOCS).